Navigation Links
NanoLogix Inc. Presents at the National Hydrogen Association Conference & Provides Operations, Management and Director Update
Date:3/31/2008

HUBBARD, Ohio, March 31 /PRNewswire-FirstCall/ -- NanoLogix, Inc. (OTC: NNLX - News) a nano-biotechnology company is pleased to provide the following updates on company events:

NanoLogix personnel are manning a booth and presenting at the National Hydrogen Association Expo in Sacramento this week, with the company being represented by William Hartman and Chris Novak. Mr. Hartman will be presenting in the Exhibition Hall today, March 31, from 2:00-2:30 pm, on "Biohydrogen and Electricity Production from Waste Water".

Company CEO Bret Barnhizer was Marlene Bourne's guest on The Bourne Report March 16, on the topic of Hydrogen Power. The interview provides updates on hydrogen bioreactor operations. Access: http://www.bournereport.com/radio.php

Work on BNC and BNP development for fast microorganism detection is proceeding at a rapid pace, with a new patent application filed in March and positive developments with both the Departments of Defense and Homeland Security in late February.

Director and Management changes: Dr. Robert Ollar and John Chatterton have joined the Board of Directors. Dr. Ollar is cofounder of NanoLogix (as Infectech), the primary author of the majority of the company's granted patents, and returns to the company after a six year hiatus. Mr. Chatterton is former co-host of the History Channel series, Deep Sea Detectives, and is one of the world's most accomplished and well known underwater explorers. David Barnhizer has joined the company as General Counsel, bringing to the company nearly forty years of legal expertise. Detailed director and management team information can be accessed at: http://www.nanologixinc.com/index-2.html

General Counsel David Barnhizer stated: "NNLX is poised to make a significant move forward under its new board of directors and management team headed by CEO and Board Chairman Bret Barnhizer and complemented by a reformed and greatly strengthened board of directors. A skilled and knowledgeable team of professionals whose members are fully dedicated to the advancement of NanoLogix has been put into place. As NNLX General Counsel I am extremely pleased to be associated with a group of professionals committed to the building of an exceptional company whose patented technologies are on the cutting edge of hydrogen energy extraction from industrial and commercial wastes, as well as diagnostic tools that are drawing the attention of governmental and commercial institutions."

The company has accepted the resignations of directors Hartman, Allan, and Cavallo from all positions held. Mr. Hartman will continue to provide business consulting services to NanoLogix.

About NanoLogix, Inc.

NanoLogix is a leading innovator in the research, development, and commercialization of nano-biotechnologies, applications and processes. The Company has 31 granted Patents and multiple Patents Pending for bioreactor- based Hydrogen Production, revolutionary rapid medical testing technologies, and bioremediation. Information on NanoLogix is available at http://www.nanologixinc.com.

This press release contains statements, which may constitute "forward- looking statements" within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Those statements include statements regarding the intent, belief or current expectations of NanoLogix, Inc., and members of its management as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. The Company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results.

Contact:

Investor Relations

Bret Barnhizer, CEO

Telephone: 330-534-0800

E-mail: Bret@nanologixinc.com


'/>"/>
SOURCE NanoLogix, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. National Public Radio (NPR) Features Broadcast Articles on NanoLogix Hydrogen Bioreactor Operation at Welchs Foods
2. NanoLogixs Hydrogen-From-Waste Technology at Welchs Foods Featured on Environmental Radio Program
3. NanoLogix, Inc. Makes Stock Pick List
4. NanoLogix Inc. Sets Date for Annual Shareholder Meeting and Provides Shareholder Update
5. NanoLogix Inc. to Present at EBW Expo & Conference 2007
6. NanoLogix Inc. Announces Historical First in Energy Generation With Bioreactor-Produced Hydrogen at Welchs
7. NanoLogix Inc. Appoints Director of IP and Makes Progress on Rapid Anthrax Detection
8. Amicus Therapeutics Presents Positive Data from Phase 2 Clinical Trial of Plicera(TM) for Gaucher Disease
9. Halozyme Therapeutics Presents Favorable New Safety and Pharmacokinetic Data on rHuPH20 Enzyme Produced Via New Manufacturing Process at European Federation for Pharmaceutical Sciences
10. Alseres Pharmaceuticals Presents Inosine and Dopamine Transporter (DAT) Blocker Preclinical Data at the American Society for Experimental NeuroTherapeutics (ASENT) Conference
11. Dr. Mark Nestor Presents on Pyratine-6(TM) at the South Beach Symposium
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)...  Regular discussions on a range of subjects including policies, ... entities said Poloz. Speaking at a lecture to ... he pointed to the country,s inflation target, which is set ... "In certain areas there needs ... economic goals, why not sit down and address strategy together?" ...
(Date:6/24/2016)... ... June 24, 2016 , ... Researchers at the Universita ... miRNAs in people with peritoneal or pleural mesothelioma. Their findings are the subject of ... now. , Diagnostic biomarkers are signposts in the blood, lung fluid or tissue ...
(Date:6/23/2016)... 2016   Boston Biomedical , an industry ... to target cancer stemness pathways, announced that its ... Drug Designation from the U.S. Food and Drug ... including gastroesophageal junction (GEJ) cancer. Napabucasin is an ... cancer stemness pathways by targeting STAT3, and is ...
(Date:6/23/2016)... 2016 Houston Methodist Willowbrook Hospital has ... Association to serve as their official health care ... Willowbrook will provide sponsorship support, athletic training services, ... coaches, volunteers, athletes and families. "We ... Association and to bring Houston Methodist quality services ...
Breaking Biology Technology:
(Date:6/21/2016)... Columbia , June 21, 2016 ... to the new role of principal product architect ... named the director of customer development. Both will ... chief technical officer. The moves reflect NuData,s strategic ... in response to high customer demand and customer ...
(Date:6/15/2016)... , June 15, 2016 ... market report titled "Gesture Recognition Market by Application Market - Global ... 2016 - 2024". According to the report, the  global ... billion in 2015 and is estimated to grow ... 48.56 billion by 2024.  Increasing application ...
(Date:6/7/2016)... , June 7, 2016  Syngrafii Inc. ... a business relationship that includes integrating Syngrafii,s patented ... branch project. This collaboration will result in greater ... the credit union, while maintaining existing document workflow ... http://photos.prnewswire.com/prnh/20160606/375871LOGO ...
Breaking Biology News(10 mins):